MindWalk Holdings Corp. income statement HYFT

Annual Quarterly

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line
FY 2025
Apr 30, 2025
FY 2024
Apr 30, 2024
FY 2023
Apr 30, 2023
FY 2022
Apr 30, 2022
FY 2021
Apr 30, 2021
Weighted average shares, basic
33
+30.2%
26
+3.0%
25
+26.5%
20
+19.5%
16
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
HYFT (Nasdaq)
Fiscal year ends
April 30
Incorporated in
British Columbia, Canada
Headquarters
Victoria
SEC filer status
Non-accelerated filer
SEC CIK
1715925
Former names
ImmunoPrecise Antibodies Ltd. (until Sep 3, 2025)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.